# Mean Corpuscular Volume as a Prognostic Marker in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection: A Cohort Study

**Authors:** Soomin An, Wankyu Eo

PMC · DOI: 10.3390/medicina62020395 · Medicina · 2026-02-18

## TL;DR

This study finds that mean corpuscular volume (MCV) can help predict survival in lung cancer patients after surgery when combined with another score.

## Contribution

The study introduces a composite index combining MCV with the NUn score to improve survival prediction in NSCLC patients.

## Key findings

- Preoperative MCV independently predicts overall survival in resected NSCLC patients.
- A composite NUn–MCV index improves survival prediction compared to anatomical staging alone.
- The full model with NUn–MCV showed better discriminative ability than baseline and intermediate models.

## Abstract

Background and Objectives: Anatomical staging alone insufficiently explains survival heterogeneity in patients with resected non-small cell lung cancer (NSCLC). Although inflammation-based biomarkers have demonstrated prognostic value, the clinical relevance of erythrocyte-derived indices—particularly mean corpuscular volume (MCV)—remains poorly characterized in this setting. This study evaluated the prognostic significance of preoperative MCV and examined whether its integration with the Noble and Underwood (NUn) score improves survival prediction. Methods: We retrospectively analyzed patients with stage I–IIIA NSCLC who underwent complete surgical resection. Associations between clinicopathological variables and overall survival (OS) were assessed using Cox proportional hazards models. Prognostic performance was evaluated using the concordance index and the integrated time-dependent area under the curve. Continuous variables were modeled on their original scale without dichotomization. Results: Model comparison using the Akaike Information Criterion indicated that incorporation of the composite NUn–MCV index into the intermediate model—comprising age, basal metabolic rate, American Society of Anesthesiologists physical status, pleural invasion, and pathological stage—provided a superior model fit compared with inclusion of the NUn score and MCV as separate covariates. On this basis, the composite NUn–MCV model was selected as the full model. Across all evaluations, the full model demonstrated consistently greater discriminative ability for survival prediction than both the intermediate model and the baseline model based solely on pathological stage. Conclusions: Preoperative MCV independently predicts OS in patients with resected stage I–IIIA NSCLC. Integration of MCV with the NUn score into a composite index provides incremental prognostic value beyond anatomical staging and established clinical factors, supporting its use as a complementary tool for postoperative risk stratification.

## Linked entities

- **Diseases:** non-small cell lung cancer (MONDO:0005233), NSCLC (MONDO:0005233)

## Full-text entities

- **Genes:** HAMP (hepcidin antimicrobial peptide) [NCBI Gene 57817] {aka HEPC, HFE2B, LEAP1, PLTR}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, EPO (erythropoietin) [NCBI Gene 2056] {aka DBAL, ECYT5, EP, MVCD2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ITIH1 (inter-alpha-trypsin inhibitor heavy chain 1) [NCBI Gene 3697] {aka H1P, IATIH, ITI-HC1, ITIH, SHAP}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, PMCH (pro-melanin concentrating hormone) [NCBI Gene 5367] {aka MCH, ppMCH}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}
- **Diseases:** thyroid dysfunction (MESH:D013959), stage I-IIIA (MESH:D009084), macrocytosis (MESH:C564004), TNM (MESH:D008207), MCV (MESH:D009800), anemia (MESH:D000740), metastases (MESH:D009362), hypothyroidism (MESH:D007037), nutritional deficiencies (MESH:D044342), death (MESH:D003643), connective tissue disease (MESH:D003240), folate deficiencies (MESH:C562799), infection (MESH:D007239), stage II or IIIA disease (MESH:D007676), hypoxic (MESH:D002534), Vitamin B12 (MESH:D014806), stage IIIB or IV disease (MESH:C566890), FM (MESH:D004195), myelodysplastic syndromes (MESH:D009190), NSCLC (MESH:D002289), large cell carcinoma (MESH:D018287), squamous cell carcinoma (MESH:D002294), Hypoxia (MESH:D000860), inflammation (MESH:D007249), liver disease (MESH:D008107), disease (MESH:D004194), injury to (MESH:D014947), small cell lung cancer (MESH:D055752), Lung cancer (MESH:D008175), IIIA (MESH:C566889), PL (MESH:D010995), Malignancy (MESH:D009369), adenocarcinoma (MESH:D000230), cancers of the head and neck, esophagus, stomach, and colorectum (MESH:D006258)
- **Chemicals:** vitamin B12 (MESH:D014805), Alcohol (MESH:D000438), folate (MESH:D005492), ASA (MESH:D001241), iron (MESH:D007501), oxygen (MESH:D010100), bilirubin (MESH:D001663), EDTA (MESH:D004492)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943322/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943322/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943322/full.md

---
Source: https://tomesphere.com/paper/PMC12943322